Azenta Stock (NASDAQ:AZTA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$37.50

52W Range

$23.91 - $55.64

50D Avg

$32.22

200D Avg

$31.32

Market Cap

$1.61B

Avg Vol (3M)

$628.40K

Beta

1.29

Div Yield

-

AZTA Company Profile


Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3,000

IPO Date

Feb 02, 1995

Website

AZTA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceSep 25Sep 24Sep 22
Product$173.19M$243.41M$180.95M
Service$420.63M$412.92M$374.55M

Fiscal year ends in Sep 25 | Currency in USD

AZTA Financial Summary


Sep 25Sep 24Sep 23
Revenue$593.82M$656.32M$665.07M
Operating Income$24.46M$-200.68M$-73.13M
Net Income$-59.50M$-164.17M$-14.26M
EBITDA$-26.84M$17.85M$55.15M
Basic EPS$-1.30$-3.09$-0.22
Diluted EPS$-1.30$-3.09$-0.22

Fiscal year ends in Sep 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Nov 21, 25 | 8:30 AM
Q3 25Aug 05, 25 | 8:30 AM
Q2 25May 07, 25 | 8:30 AM

Peer Comparison


TickerCompany
KMTSKESTRA MEDICAL TECHNOLOGIES, LTD.
ESTAEstablishment Labs Holdings Inc.
SDGRSchrödinger, Inc.
EVOEvotec SE
SYRESpyre Therapeutics, Inc.
NEOGNeogen Corporation
BLFSBioLife Solutions, Inc.
STAASTAAR Surgical Company
TDOCTeladoc Health, Inc.
NVCRNovoCure Limited